According to the university, new nanotech scaffolding can be used to support tissue growth.
Pusan National University announced a potential breakthrough in muscle regeneration technology. Researchers at the university studied MXene nanoparticles (NP) in an attempt to better understand how these nanoparticles work.
In a press release, the university details how a team of researchers used DNA sequencing on nanofibrous matrices which contained MXene NPs. The results revealed the genes and biological pathways that were activated by the NPs.
This is considered a breakthrough because up until these findings, the specific mechanism these NPs used to promote muscles was unclear to researchers. Prior to this, MXene NPs were only shown in laboratory demonstrations to promote growth.
The team of researchers includes associate professor Yun Hak Kim, professor Suck Won Hong, and professor Dong-Wook Han. Kim is from the Department of Anatomy and the Department of Biomedical Informatics, while Hong and Han are from the Department of Cogno-Mechatronics Engineering.
MXene NPs could potentially be used in place of traditional muscle grafts.
In the press release, Kim said, “This discovery posits a prospective avenue for the utilization of these materials to augment the efficacy of muscle tissue regeneration post-injury or damage.”
According to the findings, MXene NPs promote calcium ion deposition around cells, which then triggers the activation of certain genes. These specific genes produce various proteins while also increasing the production of nitrous oxide. The combined result promotes muscle growth.
Now that the researchers have a better understanding of how MXene NPs work, they say that they have a chance to refine the designs of the scaffolds these NPs are used in to achieve better and more efficient results. Kim believes that this research could lead to significant improvements in muscle injury treatments within five to 10 years.
(Jan. 19, 2024); Pusan National University; Pusan National University's Breakthrough in Muscle Regeneration: Nanotech Scaffolding Supports Tissue Growth; https://www.prnewswire.com/news-releases/pusan-national-universitys-breakthrough-in-muscle-regeneration-nanotech-scaffolding-supports-tissue-growth-302038635.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.